Skye Bioscience, Inc./$SKYE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Skye Bioscience, Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
Ticker
$SKYE
Sector
Primary listing
Employees
12
Headquarters
Website
SKYE Metrics
BasicAdvanced
$29m
-
-$1.45
-
-
Price and volume
Market cap
$29m
52-week high
$5.75
52-week low
$0.57
Average daily volume
195k
Financial strength
Current ratio
1.784
Quick ratio
1.644
Total debt to equity
3.455
Interest coverage (TTM)
-79,087.51%
Profitability
EBITDA (TTM)
-58.36
Effective tax rate (TTM)
-0.01%
Management effectiveness
Return on assets (TTM)
-87.69%
Return on equity (TTM)
-167.97%
Valuation
Price to book
3.23
Price to tangible book (TTM)
3.23
Price to free cash flow (TTM)
-0.775
Free cash flow yield (TTM)
-129.11%
Free cash flow per share (TTM)
-1.07
Growth
Earnings per share change (TTM)
74.71%
3-year earnings per share growth (CAGR)
-43.64%
10-year earnings per share growth (CAGR)
-32.92%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs